Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm

Background Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheila Kansiime, Christian Holm Hansen, Henry Bern, Julie Fox, David Dunn, Eugene Ruzagira, Richard Hayes, Sheena Mc Cormack, on behalf of the PrEPVacc study team
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:HIV Research & Clinical Practice
Subjects:
pre-exposure prophylaxis
counterfactual placebo hiv incidence
adherence-efficacy
non-inferiority pre-exposure prophylaxis trials
emtricitabine/tenofovir
Online Access:http://dx.doi.org/10.1080/25787489.2025.2513684
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1080/25787489.2025.2513684

Similar Items